The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast

Journal of Clinical Pathology

Volumn 60, Issue 3, 2007, Pages 315-320

  Tse, G M K ^a,b   Tan, P H ^c   Lui, P C W ^b   Gilks, C B ^d   Poon, C S P ^e   Ma, T K F ^e   Law, B K B ^f   Lam, W W M ^g  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e NORTH DISTRICT HOSPITAL   (Hong Kong)

^f Union Hospital   (Hong Kong)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 14; PROTEIN P63; SMOOTH MUSCLE ACTIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EPITHELIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PAPILLOMA; PRIORITY JOURNAL;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; KERATIN-14; MIDDLE AGED; NEOPLASM PROTEINS; NEPRILYSIN; PAPILLOMA; PAPILLOMA, INTRADUCTAL; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 33947432040     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.036830     Document Type: Article

References (42)

1. Haagensen CD, Stout AP, Philips JS. The papillary neoplasms of the breast. I. Benign intraductal papilloma. Ann Surg 1951;133:18-36.
2. Kraus FT, Neubecker RD. The differential diagnosis of papillary tumours of the breast. Cancer 1962;15:444-55.
3. Murad TM, Contesso G, Mouriesse H. Papillary tumours of large lactiferous ducts. Cancer 1981;48:122-33.
4. Oyama T, Koerner FC. Noninvasive papillary proliferations. Semin Diagn Pathol 2004;21:32-41.
5. Ellis IO, Elston CW, Pinder SE. Papillary lesions. In: Elston CW, Ellis IO, eds. The breast. Systemic pathology, 3rd edn, Vol 13. Edinburgh, UK: Churchill Livingston, 1998:133-46.
6. Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol 2005;123:36-44.
7. Page DL, Anderson TJ. Papilloma and related lesions. In: Page DL, Anderson TJ, eds. Diagnostic histopathology of the breast. Edinburgh, UK: Churchill Livingston, 1987:104-19.
8. Papotti M, Eusebi V, Gugliotta P, et al. Immunohistochemical analysis of benign and malignant papillary lesions of the breast. Am J Surg Pathol 1983;7:451-61.
9. Raju UB, Lee MW, Zarbo RJ, et al. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms. Mod Pathol 1989;2:569-76.
10. Mosunjac MB, Lewis MM, Lawson D, et al. Use of a novel marker, calponin, for myoepithelial cells in fine-needle aspirates of papillary breast lesions. Diagn Cytopathol 2000;23:151-5.
11. Zhang C, Zhang P, Hao J, et al. High nuclear grade, frequent mitotic activity, cyclin D1 and p53 overexpression are associated with stromal invasion in mammary intracystic papillary carcinoma. Breast J 2005;11:2-8.
12. Tan PH, Aw MY, Yip G, et al. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol 2005;29:625-32.
13. Saddik M, Lai R. CD44s as a surrogate marker for distinguishing intraductal papilloma from papillary carcinoma of the breast. J Clin Pathol 1999;52:862-4.
14. Tse GM, Tan PH, Ma TK, et al. CD44 is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol 2005;58:1185-8.
15. Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001;25:1054-60.
16. Ribeiro-Silva A, Zambelli Ramalho LN, Britto Garcia S, et al. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 2003;127:336-40.
17. Reis-Filho JS, Milanezi F, Amendoeira I, et al. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples. Cancer 2003;99:172-9.
18. Reis-Filho JS, Milanezi F, Amendoeira I, et al. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. J Clin Pathol 2002;55:936-9.
19. Ribeiro-Silva A, Zamzelli Ramalho LN, Garcia SB, et al. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? Pathol Oncol Res 2003;9:20-3.
20. Stefanou D, Batistatou A, Nonni A, et al. p63 expression in benign and malignant breast lesions. Histol Histopathol 2004;19:465-71.
21. Hoda SA, Rosen PP. Practical considerations in the pathologic diagnosis of needle core biopsies of breast. Am J Clin Pathol 2002;118:101-8.
22. Agoff SN, Lawton TJ. Papillary lesions of the breast with and without atypical ductal hyperplasia: can we accurately predict benign behavior from core needle biopsy? Am J Clin Pathol 2004;122:440-3.
23. Carder PJ, Garvican J, Haigh I, et al. Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast. Histopathology 2005;46:320-7.
24. Ivan D, Selinko V, Sahin AA, et al. Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: histological predictors of malignancy. Mod Pathol 2004;17:165-71.
25. Renshaw AA, Derhagopian RP, Tizol-Blanco DM, et al. Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision. Am J Clin Pathol 2004;122:217-21.
26. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-13.
27. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-18.
28. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumour tissues. Clin Cancer Res 2002;8:494-501.
29. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-30.
30. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004;28:1506-12.
31. Tse GM, Tan PH, Chaiwun B, et al. p63 is useful in the diagnosis of mammary metplastic carcinomas. Pathology 2006;38:16-20.
32. Greaves MF, Brown G, Rapson NT, et al. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol 1975,4:67-84.
33. Chu P, Arber DA. Paraffin section detection of CD10 in 505 nonhematopoietic neoplasms. Am J Clin Pathol 2000;113:374-82.
34. Chu P, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumours: an immunohistochemical comparison of 34 cases. Mod Pathol 2001;14:465-71.
35. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273- 8.
36. Moritani S, Kushima R, Sugihara H, et al. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002;15:397-405.
37. Tse GM, Tsang AK, Pulti TC, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005;58:185-9.
38. Bocker W, Bier B, Freytag G, et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I: normal breast and benign proliferative lesions. Virchows Arch A Pathol Anat Histopathol 1992;421:315-22.
39. Tsubura A, Okada H, Senzaki H, et al. Keratin expression in the normal breast and in breast carcinoma. Histopathology 1991;18:517-22.
40. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-71.
41. Otterbach F, Bankfalvi A, Bergner S, et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000;37:232-40.
42. Wetzels RH, Kuijpers HJ, Lane EB, et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 1991;138:751-63.